NeuroOne expects FY25 revenue to reach $8M-$10M as OneRF platform advances and new FDA submission broadens pipeline

Stock Information for NeuroOne Medical Technologies Corporation

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NeuroOne Medical Technologies Corporation

NeuroOne® to Participate in Sidoti Small-Cap Conference on September 17th and 18th, 2025
NeuroOne® Receives FDA 510(k) Clearance for OneRF® Trigeminal Nerve Ablation System to Treat Facial Pain
NeuroOne® Reports Third Quarter Fiscal Year 2025 Financial Results; Revenue Increases 105% YoY and Gross Margin Expands to 53.9%
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time - Update
NeuroOne® to Report Third Quarter Fiscal Year 2025 Financial Results on Thursday, August 14 at 8:30 a.m. Eastern Time
NeuroOne® Receives Notice of Allowance for Key Patent from U.S. Patent & Trademark Office
NeuroOne® Patient Surpasses One Year Milestone of Seizure Freedom Following Treatment with OneRF® Ablation System
NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.